Breast Oncology
Breast Oncology
The Breast Oncology Center at the Susan F. Smith Center for Women's Cancers at Dana-Farber provides state-of-the-art and compassionate care for breast cancer patients. Our breast cancer clinicians are committed to providing your patients with the best and most individualized treatment options available, including the latest medical oncology, surgical options, breast reconstruction, and radiation therapy.
Our focused and specialized services include programs for: young adults with breast cancer, metastatic breast cancer, inflammatory breast cancer, breast cancer during pregnancy, breast and ovarian cancer genetics and prevention, older adults with breast cancer, patients with breast cancer brain metastases, breast cancer in men, and ductal carcinoma in situ (DCIS).
View Treatment Guidelines and Other Resources Learn About Breast Cancer Breakthroughs Webinar: Updates in the Diagnosis and Management of Inflammatory Breast Cancer for ProvidersFeatured Content |view more
News
Building a System of Focused Care for Lobular Breast Cancer
How Dana-Farber investigators are pioneering new approaches to help understand, diagnose, and treat this distinct form of breast cancer
News
The U.S. Food and Drug Administration (FDA) has approved a new therapy regimen for patients with “double-positive” metastatic breast cancer based on results of the phase 3 PATINA study led by Otto Metzger, MD, Associate Medical Director ...
Video
ASCO26: Sara Tolaney, MD, MPH, ASCENT-03
Dana-Farber Cancer Institute's Dr. Sara Tolaney from the ASCENT-03 stud in breast cancer. The data further strengthens the case for approval of sacituzumab govitecan as first-line treatment for patients with advanced triple-negative breast cancer.
Video
ASCO26: Jennifer Ligibel, MD, BWEL
Dana-Farber Cancer Institute's Dr. Jennifer Ligibel shared updated results from the BWEL study showing a weight loss intervention led to significantly better physical function, global physical and mental health, and symptom in patients ...
News
The U.S. Food and Drug Administration (FDA) has approved the antibody-drug conjugate sacituzumab govitecan for first-line treatment of metastatic triple-negative breast cancer.
Document
Treatment Guideline: First-Line Treatment for Metastatic Triple-Negative Breast Cancer (TNBC)
The Breast Oncology Center held meetings to discuss recommendations regarding first-line treatment for patients with metastatic triple-negative breast cancer (TNBC).